| Characteristic | Core biopharma | Biopharma service & supply chain |
|---|---|---|
| 2022 | 70,000 | 80,000 |
| 2021 | 64,500 | 71,800 |
| 2020 | 66,000 | 63,900 |
| 2019 | 64,000 | 60,500 |
| 2018 | 63,800 | 58,300 |
| 2017 | 64,000 | 56,300 |
| 2016 | 66,300 | 55,800 |
| 2015 | 64,900 | 53,500 |
| 2014 | 62,200 | 50,400 |
| 2013 | 61,400 | 49,400 |
| 2012 | 62,900 | 47,800 |
| 2011 | 69,400 | 47,000 |
The chart is not accessible to screen readers. Please switch to the table view to access the data.
Loading statistic...
Download
Source
Source
Release date
May 2024
More information
Region
United Kingdom
Survey time period
2011 to 2022
Supplementary notes
Definition:Core biopharma: includes all businesses involved in developing and/or producing their own pharmaceutical products - from small, research and development (R&D) focused biotechs to multinational Big Pharma.
Biopharma service & supply chain: comprises businesses that offer goods and services to Core Biopharma businesses including, for example, Contract Research and Manufacturing Organisations (CRMOs), and suppliers of consumables and reagents for R&D facilities
This statistic using original data from the Government Digital Service and includes copyright material licensed under © Crown, the
Citation formats
